 | ||||
| ||||
Introduction
IPI - International Pharmaceutical Industry – was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally. One of the main reasons why clients are using us is the extensive knowledge and reach we have built up over the years with our Editor, Editorial advisory board and market research. We do not just cover issues in one marketplace, but give you links into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. Whether you are looking to highlight your own expertise or looking for that natural partnership and alliance, IPI can help. Informative articles from prominent industry figures plus exciting opportunities through our website will give value to your marketing spend to a truly global audience. Both editorially and advertising, we listen to your needs [it’s not all one way traffic]. Creating awareness through the journal, website and event attendance, we will promote your expertise globally. We have established a strong presence in the Middle East, Latin America, Eastern Europe, Asia and Africa which are becoming increasingly important to the way the industry is moving forward in areas of Research and Development, Trials, manufacturing and Technology Transfer. Come and speak with us to see if we can help you and justify your marketing spend and promotional activity. We are confident that we can provide you with a good service and also keep you in touch with your potential clients.
LETS FACE IT MEDIA HAS, AND WILL ALWAYS BE THE ONLY TRUE MEANS OF COMMUNICATIONS.
Video Blog
Your video here!
This site is run by Pharma Publications
SUPPORTING THE INDUSTRY THROUGH COMMUNICATION
The Value of Intellectual Property: An Overview of Methods Used
Although intellectual property (IP) is regarded by many as an intangible asset for some companies, especially those in the life science arena, it can be the company’s sole or primary asset. Intellectual property includes patents, trademarks, service marks, copyrights, and trade secrets. IP valuation is more than creative accounting. Dr Louise Sarup of IP Pragmatics Ltd. explains that there are a number of methods of valuation of IP, and each represents an available option. Inclusion of IP as an asset in its accounts reflects a company’s true and fair financial position. More
Quality Staff Recruitment and Retention.
In 2009 the pharmaceutical industry was affected just the same as everyone else by the economic downturn. Biotechnology companies found their funding being withdrawn or just not being there in the first place; large pharma suffered from drug pipelines drying up; and the related services industries found it difficult to win work, with their margins being squeezed hard by clients who found themselves in a very strong bargaining position. Jim Gleeson from CK Clinical explores from a purely recruitment perspective a number of effects of this turmoil. More
Patent Data – Why More is More
In order to obtain a patent, it is necessary to show that your invention is novel and inventive. One aspect of this is that the invention should make a contribution to the relevant field of research. As a result, when a patent application is filed, it ought to contain data, usually in the form of experimental results, to convince the patent office that this is the case. Care must be taken to ensure that in the rush to secure an early filing date, the need to ensure that sufficient data is included in the application at filing is not neglected. In this article Charlotte Dale and Charlotte Fox of Forresters discuss how much data a patent application should ideally contain at filing, with a focus on the views of the European Patent Office (EPO). More
Clinical Trials Insurance: Integrated Expertise and Technology Enable Precise Aim at a Moving Target
Clinical trials have gone global. According to the National Institutes of Health, a division of the US Department of Health and Human Services, there are currently more than 58,000 trials taking place in more than 150 countries. One of the main challenges life sciences companies face, however, is keeping abreast of the various insurance requirements imposed by these countries. Kathleen Burns of Aon eSolutions discusses what needs to be considered when securing appropriate clinical trials insurance, especially for multinational sites. More.
Flanders – An attractive BioPharma Cluster.
Innovation is the key word for the life sciences and biotechnology sector. Flanders has a long and successful tradition of discovery and innovation. Joke Comijn of FlandersBio explores some of the major scientific breakthroughs achieved, including the first unravelling of the DNA sequence of a gene, the discovery of tPA, a major treatment for heart failure, and the discovery of treatments for schizophrenia, pain management, gastro-intestinal disorders and parasitic infections. Innovation combined with entrepreneurship, the presence of a life sciences network of more than 145 companies with biotech activities, and numerous biopharma collaborations, have turned a small region into a world player. More.
| ||||
IPI CURRENT ISSUE FEATURES
Newsletter sign-up
| ||||
Bringing you lastest News...
| ||||
International Pharmaceutical Regulatory Monitor ..
QUALOGY
THE Science of Quality
IPI Quick guide to Pharma Terminology >> > >
Quick links to Regulatory Authorities
ARAB HEALTH ORGANISATION
